HCC Specialty Series – Efrat Dotan, MD
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
12 events found.
HCC Specialty Series – Thomas Cartwright, MD
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
CRC Grand Rounds – Kailua, HI
This live activity will cover the treatment and management of patients with refractory metastatic colorectal cancer (CRC).
HCC Specialty Series – Stanley Cohen, MD
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
TRK Fusion + Cancers – Grand Junction, CO
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
HCC Specialty Series – Stanley Cohen, MD
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
A 3D View of Genomics, Targeted Therapeutic Options, and Treatment Sequencing for the Management of Hematologic Malignancies
This activity will cover the treatment and management of patients with AML and CLL.
CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Prescott, AZ
Northern Arizona VAHCS 500 N Hwy 89, Prescott, AZ, United StatesThis program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
Rethinking HCC – Bay Pines, FL
Bay Pines VA Healthcare System Building 20 Auditorium, 10,000 Bay Pines Blvd, Bay Pines, FL, United StatesThis live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
Rethinking HCC – North Las Vegas, NV (PST)
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
Rethinking HCC – Charlottesville, VA
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
Prostate Grand Rounds – Coatesville, PA
This activity will cover the treatment and management of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).